DE69936134D1 - Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren - Google Patents

Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren

Info

Publication number
DE69936134D1
DE69936134D1 DE69936134T DE69936134T DE69936134D1 DE 69936134 D1 DE69936134 D1 DE 69936134D1 DE 69936134 T DE69936134 T DE 69936134T DE 69936134 T DE69936134 T DE 69936134T DE 69936134 D1 DE69936134 D1 DE 69936134D1
Authority
DE
Germany
Prior art keywords
recombinant
viruses
production
adenovires
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69936134T
Other languages
English (en)
Inventor
Tong-Chuan He
Bert Vogelstein
Kenneth W Kinzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69936134D1 publication Critical patent/DE69936134D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69936134T 1998-02-27 1999-02-25 Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren Expired - Lifetime DE69936134D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/031,917 US5922576A (en) 1998-02-27 1998-02-27 Simplified system for generating recombinant adenoviruses
PCT/US1999/004062 WO1999043843A1 (en) 1998-02-27 1999-02-25 A simplified system for generating recombinant adenoviruses

Publications (1)

Publication Number Publication Date
DE69936134D1 true DE69936134D1 (de) 2007-07-05

Family

ID=21862097

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69936134T Expired - Lifetime DE69936134D1 (de) 1998-02-27 1999-02-25 Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren

Country Status (7)

Country Link
US (1) US5922576A (de)
EP (1) EP1056881B1 (de)
AT (1) ATE362989T1 (de)
AU (1) AU747847B2 (de)
CA (1) CA2322066A1 (de)
DE (1) DE69936134D1 (de)
WO (1) WO1999043843A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US6420629B1 (en) * 1996-09-09 2002-07-16 B.C. Research Inc. Process of increasing plant growth and yield and modifying cellulose production in plants
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP0968284B1 (de) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
CA2294649C (en) 1997-06-23 2007-09-25 University Of Saskatchewan Bovine adenovirus type 3 genome
EP1068350B1 (de) * 1998-03-28 2008-02-13 University Of Utah Research Foundation Zielgerichtete antisense-bibliotheken
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP2002528056A (ja) 1998-08-28 2002-09-03 デューク・ユニバーシティー ＩＶａ２、１００Ｋ及び／又は末端前タンパク質配列における欠失型アデノウイルス
US6303362B1 (en) * 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
DE60017924T2 (de) * 1999-09-17 2006-03-30 Tgt Laboratories, S.A. De C.V. Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
US6867022B1 (en) * 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
AU2001234980A1 (en) * 2000-02-09 2001-08-20 Genvec, Inc. Methods of preparing and using a viral vector library
US6830920B2 (en) * 2000-03-08 2004-12-14 University Of Iowa Research Foundation Rapid generation of recombinant adenoviral vectors
EP1285079A2 (de) * 2000-05-31 2003-02-26 University of Saskatchewan Modifizierter boviner adenovirus mit geändertem tropismus
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
AU2001288839A1 (en) 2000-09-08 2002-03-22 The General Hospital Corporation Self-rearranging dna vectors
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
WO2002038783A1 (en) * 2000-11-10 2002-05-16 Astrazeneca Ab Vector
GB0027501D0 (en) * 2000-11-10 2000-12-27 Astrazeneca Ab Vector
MXPA00011713A (es) * 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
US20020177229A1 (en) * 2001-01-19 2002-11-28 Ivo Piest Swap/counter selection: a rapid cloning method
US6838285B2 (en) 2001-09-18 2005-01-04 Becton Dickinson Site specific recombinase based method for producing adenoviral vectors
EP1516055A4 (de) * 2002-01-24 2007-08-08 Scripps Research Inst Faserschaftmodifikationen für effizientes zielen
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
CA2485341A1 (en) * 2002-05-08 2004-06-17 Intronn, Inc. Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
WO2004028243A2 (en) 2002-08-21 2004-04-08 Revivicor, Inc. Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
CN1701120A (zh) * 2002-09-27 2005-11-23 磨粉机械研究有限公司 用于基因表达的核酸构建体
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2005001133A2 (en) * 2003-06-03 2005-01-06 Collateral Therapeutics, Inc. Compositions and methods for high throughput construction and functional analysis of expression libraries
JP5698426B2 (ja) * 2003-06-10 2015-04-08 ユニバーシティ オブ サスカチュワン キメラアデノウイルスキャプシドタンパク質
US20070213288A1 (en) * 2003-07-17 2007-09-13 University Of South Florida Adenoviral Vector Capable of Infecting Tumor Cells and Eliminating the Function of STAT3
US20070003520A1 (en) * 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
US7897146B2 (en) * 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
JP2007518423A (ja) * 2004-01-23 2007-07-12 イントロン、インコーポレイテッド スプライセオソーム仲介型ｒｎａトランススプライシングを使用するアポａ−１及びその変異体の発現
WO2005070948A1 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
CA2574953A1 (en) 2004-07-26 2006-02-09 Dow Global Technolgies Inc. Process for improved protein expression by strain engineering
WO2006073496A2 (en) * 2004-07-30 2006-07-13 Targeted Genetics Corporation Recombinant aav based vaccine methods
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
EP1831365B1 (de) * 2004-10-08 2013-08-07 VIRxSYS Corporation Verwendung von rns trans-splicing zum antikörper gen transfer und zur antikörperherstellung
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
WO2006052302A2 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying adenoviral vectors
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
KR20080052512A (ko) * 2005-05-23 2008-06-11 박신, 인크. 아데노바이러스-무함유 재조합 아데노바이러스 벡터의 급속생산
AU2006292827B2 (en) 2005-08-09 2013-02-14 Revivicor, Inc. Transgenic ungulates expressing CTLA4-IG and uses thereof
KR100723009B1 (ko) 2005-11-30 2007-05-29 한국원자력연구원 인간 ｐ３１ 유전자를 함유하는 악성 종양 치료용 약학적조성물
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
CL2007001011A1 (es) 2006-04-11 2008-05-16 Arena Pharm Inc Metodo para la identificacion de secretagogos de gip, polipeptido inhibidor gastrico; y uso de un receptor acoplado a proteina g para clasificar compuestos de prueba como secretagogos de gip.
EP1900749A1 (de) 2006-09-12 2008-03-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nukleinsäuren zur Expression von Polynukleotiden in Säuger-Krebszellen
EP2426142A3 (de) 2006-10-16 2012-06-13 Genelux Corporation Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN101688213A (zh) 2007-04-27 2010-03-31 陶氏环球技术公司 用于快速筛选微生物宿主以鉴定某些在表达异源蛋白质方面具有改善的产量和/或质量的菌株的方法
WO2008156655A2 (en) * 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
EP2612868B1 (de) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunsuppressive Polypeptide und Nucleinsäuren
EP2146210A1 (de) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
JP6415977B2 (ja) 2011-04-15 2018-10-31 ジェネラックス・コーポレイションＧｅｎｅｌｕｘ Ｃｏｒｐｏｒａｔｉｏｎ 弱毒化ワクシニアウイルスのクローン株およびその使用方法
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN113088530A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
CN111549065B (zh) * 2020-04-01 2023-11-24 广州医科大学附属第一医院（广州呼吸中心） 应用腺病毒转导制备能够表达人源apn转基因非人动物的方法，及所得动物的应用
WO2024011250A1 (en) 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
WO1998032860A1 (en) * 1997-01-28 1998-07-30 Baxter International Inc. Methods for highly efficient generation of adenoviral vectors

Also Published As

Publication number Publication date
EP1056881A1 (de) 2000-12-06
EP1056881B1 (de) 2007-05-23
CA2322066A1 (en) 1999-09-02
AU2787599A (en) 1999-09-15
US5922576A (en) 1999-07-13
AU747847B2 (en) 2002-05-23
WO1999043843A1 (en) 1999-09-02
ATE362989T1 (de) 2007-06-15

Similar Documents

Publication Publication Date Title
DE69936134D1 (de) Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren
McGrory et al. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5
CN105518138B (zh) CRISPR-Cas9特异性敲除猪GFRA1基因的方法及用于特异性靶向GFRA1基因的sgRNA
CN105518137B (zh) CRISPR-Cas9特异性敲除猪SALL1基因的方法及用于特异性靶向SALL1基因的sgRNA
FI111384B (fi) Menetelmä modifioidun selkärankaispoxviruksen molekylaariseksi kloonaamiseksi, modifioitu virus, sen DNA ja sen käyttö
NZ269019A (en) Method of inducing transduction with retroviral assistance
NZ316389A (en) Retroviral packaging plasmid and methods of use thereof
WO2002014495A3 (en) Enhanced homologous recombination mediated by lambda recombination proteins
CA2321964A1 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus
WO2016080795A1 (ko) 두 개의 벡터로부터 발현된 cas9 단백질을 이용한 유전자 발현 조절 방법
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
DE69534902D1 (de) Rekombinanter viraler DNS Vektor zur Transfektion tierischer Zellen
AU7075691A (en) Vaccines
DE69634043D1 (de) Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie
DE69828193D1 (de) Hyaluronan synthase gen und seine verwendung
DE60225545D1 (de) Verstärkte herstellung rekombinanter proteine mitthsenden säugerzellen
CN108795986A (zh) 一种a型血友病慢病毒载体、慢病毒及其制备方法和应用
TR200001046T2 (tr) Homolog rekombinasyonda pozitif-negatif seçimi.
HUP9904329A2 (hu) Herpeszvirus saimiri mint vírusvektor
DK0843731T3 (da) Adenovirusvektorer til genterapi
JP6667432B2 (ja) 遺伝子移入促進因子プロトランスズジン（Ｐｒｏｔｒａｎｓｄｕｚｉｎ）Ｂ
BRPI0414670A (pt) método para preparar uma célula, célula, métodos para fornecer uma célula e para gerar uma batelada de adenovìrus recombinante, molécula recombinante, conjunto de pelo menos duas moléculas de ácido nucleico, e, sistema de empacotamento
DK0880594T3 (da) Retroviral vektor og dens anvendelse i genterapi
Riedl et al. Rescue of Recombinant Adenoviruses by CRISPR/Cas-Mediated in vivo Terminal Resolution
CN1252274C (zh) 用于将外源基因导入气道上皮细胞的重组仙台病毒载体

Legal Events

Date Code Title Description
8332 No legal effect for de